Have your own idea? Try our Stock Screener
Hong Kong (HSI) Pharma Industry Analysis
UpdatedMar 06, 2026
DataAggregated Company Financials
Companies43
- 7D-5.5%
- 3M-10.2%
- 1Y45.3%
- YTD-4.4%
Over the last 7 days, the Pharma industry has dropped 5.5%, driven by a pullback from Hansoh Pharmaceutical Group of 5.0%. On the other hand Antengene is actually up 18%. In the past year, the industry has gained 45%. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the Hong Kong Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 06 Mar 2026 | HK$744.5b | HK$498.7b | HK$30.4b | 12.3x | 24.5x | 1.5x |
| Sun, 01 Feb 2026 | HK$819.7b | HK$494.1b | HK$30.3b | 13.3x | 27.1x | 1.7x |
| Tue, 30 Dec 2025 | HK$783.5b | HK$488.2b | HK$29.9b | 13x | 26.2x | 1.6x |
| Thu, 27 Nov 2025 | HK$829.9b | HK$483.6b | HK$30.2b | 13.6x | 27.4x | 1.7x |
| Sat, 25 Oct 2025 | HK$777.6b | HK$480.0b | HK$30.1b | 13.7x | 25.8x | 1.6x |
| Mon, 22 Sep 2025 | HK$801.5b | HK$479.6b | HK$30.6b | 14x | 26.2x | 1.7x |
| Wed, 20 Aug 2025 | HK$808.2b | HK$475.9b | HK$31.5b | 12.3x | 25.7x | 1.7x |
| Fri, 18 Jul 2025 | HK$728.7b | HK$475.2b | HK$29.1b | 12.5x | 25.1x | 1.5x |
| Sun, 15 Jun 2025 | HK$666.8b | HK$476.7b | HK$28.8b | 11.5x | 23.1x | 1.4x |
| Tue, 13 May 2025 | HK$493.5b | HK$473.7b | HK$28.9b | 11.1x | 17.1x | 1x |
| Thu, 10 Apr 2025 | HK$454.7b | HK$463.4b | HK$28.4b | 9.4x | 16x | 1x |
| Sat, 08 Mar 2025 | HK$452.2b | HK$464.2b | HK$31.9b | 8.6x | 14.2x | 1x |
| Mon, 03 Feb 2025 | HK$410.5b | HK$464.4b | HK$32.0b | 8.5x | 12.8x | 0.9x |
| Wed, 01 Jan 2025 | HK$433.0b | HK$459.8b | HK$31.7b | 8.6x | 13.6x | 0.9x |
| Fri, 29 Nov 2024 | HK$441.7b | HK$462.5b | HK$31.5b | 8.1x | 14x | 1x |
| Sun, 27 Oct 2024 | HK$482.4b | HK$470.9b | HK$32.7b | 7.9x | 14.7x | 1x |
| Tue, 24 Sep 2024 | HK$445.2b | HK$476.6b | HK$33.1b | 7.5x | 13.5x | 0.9x |
| Thu, 22 Aug 2024 | HK$442.6b | HK$465.9b | HK$32.8b | 7.5x | 13.5x | 1x |
| Sat, 20 Jul 2024 | HK$431.5b | HK$457.8b | HK$32.5b | 7.5x | 13.3x | 0.9x |
| Mon, 17 Jun 2024 | HK$466.3b | HK$463.2b | HK$33.9b | 8.3x | 13.8x | 1x |
| Wed, 15 May 2024 | HK$488.5b | HK$463.4b | HK$33.7b | 8.9x | 14.5x | 1.1x |
| Fri, 12 Apr 2024 | HK$447.4b | HK$464.8b | HK$33.8b | 7.6x | 13.2x | 1x |
| Sun, 10 Mar 2024 | HK$439.1b | HK$470.9b | HK$33.5b | 8x | 13.1x | 0.9x |
| Tue, 06 Feb 2024 | HK$391.4b | HK$472.8b | HK$33.8b | 6.4x | 11.6x | 0.8x |
| Thu, 04 Jan 2024 | HK$485.8b | HK$472.3b | HK$33.8b | 8.1x | 14.4x | 1x |
| Sat, 02 Dec 2023 | HK$520.0b | HK$473.1b | HK$32.2b | 7.5x | 16.1x | 1.1x |
| Mon, 30 Oct 2023 | HK$466.7b | HK$469.0b | HK$31.5b | 6.5x | 14.8x | 1x |
| Wed, 27 Sep 2023 | HK$428.8b | HK$469.1b | HK$31.5b | 6.8x | 13.6x | 0.9x |
| Fri, 25 Aug 2023 | HK$427.5b | HK$447.7b | HK$30.6b | 7.8x | 14x | 1x |
| Sun, 23 Jul 2023 | HK$475.5b | HK$446.5b | HK$27.9b | 9x | 17.1x | 1.1x |
| Tue, 20 Jun 2023 | HK$518.4b | HK$447.2b | HK$27.7b | 9.6x | 18.7x | 1.2x |
| Thu, 18 May 2023 | HK$549.2b | HK$451.0b | HK$28.2b | 8.8x | 19.5x | 1.2x |
| Sat, 15 Apr 2023 | HK$581.9b | HK$454.5b | HK$28.9b | 9.2x | 20.1x | 1.3x |
| Mon, 13 Mar 2023 | HK$585.5b | HK$443.4b | HK$34.0b | 11.2x | 17.2x | 1.3x |
Price to Earnings Ratio
17.2x
Current Industry PE
- Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 24.5x which is higher than its 3-year average PE of 17.7x.
- The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.5x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 3.6% per year over the last three years.
- Meanwhile revenues for these companies have grown 4.0% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -2.36% | |
| Healthcare | -5.76% | |
| Pharma | -5.46% | |
| Pharma | -5.46% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1177 Sino Biopharmaceutical | HK$6.13 | 1.3% +HK$1.4b | 83.5% | PE24.8x | |
| 6996 Antengene | HK$3.91 | 19.6% +HK$434.7m | 25.7% | PS27.8x | |
| 3933 United Laboratories International Holdings | HK$13.20 | 1.5% +HK$394.6m | -8.6% | PE7.5x | |
| 1643 Modern Chinese Medicine Group | HK$1.51 | 19.8% +HK$180.0m | 277.5% | PE50.6x | |
| 6622 Zhaoke Ophthalmology | HK$3.37 | 3.4% +HK$60.3m | 60.5% | PS46.1x |